INTRODUCTION
============

Endometrial cancer is the most common malignancy of the female genital tract in the United States, with an estimated number of 61,380 new cases in 2017 \[[@B1]\]. The annual death rate of 6,000 in 1997 \[[@B2]\] had almost doubled to 10,920 by 2017 \[[@B1]\]. Surgery is the principal treatment for endometrial cancer, including hysterectomy, bilateral salpingo-oophorectomy, and establishment of lymph node status. However, there is currently no consensus on the therapeutic value of lymphadenectomy, and this issue remains a topic for debate.

Sentinel lymph node (SLN) mapping is expected to offer a trade-off between systematic lymphadenectomy and no dissection at all in clinical stage I patients. However, while SLN mapping in patients with endometrial cancer is increasingly credible in Western countries \[[@B3][@B4]\], Japan lags behind in this research, because of some plausible concerns. The first concern involves the tracer-injection site for SLN mapping. There are 3 possible injection sites for SLN mapping in endometrial cancer: the endometrium, the subserosa of the uterine corpus, and the uterine cervix. The former 2 are technically demanding, while the latter is technically simple and has been used favorably in Western countries. The second issues concern the possibility of false-negative results, i.e., reduced sensitivity for lymph node metastasis (LNM) because of failure to detect SLNs. Unfortunately, the ability of cervical injection to detect para-aortic SLNs is poor, and if a patient has no pelvic lymph node (PLN) metastasis, but does have para-aortic lymph node (PAN) metastasis, SLN mapping by cervical injection may result in the opportunity to establish PAN status being missed. The possibility of such an underdiagnosis of PLN−PAN+ patients is a matter of great concern. Indeed, a third of false-negative results following cervical injection were attributable to para-aortic SLN detection failure \[[@B5]\].

The aim of the present study was to clarify the clinical implications of this underdiagnosis. The importance of PLN−PAN+ should be assessed in terms of both its probability and prognostic risk. Taking the possible outcome of SLN mapping by cervical injection into account, the probability of PAN metastasis in patients without PLN metastasis is a more appropriate endpoint of this study than the probability of PAN metastasis in all patients (patients with and without PLN metastasis). We investigated both the probability of PAN metastasis in patients without PLN metastasis and biological nature of PLN−PAN+ in terms of its aggressivity. Finally, we consider the implications of failing to search for PAN in patients without PLN metastasis.

MATERIALS AND METHODS
=====================

1. Patients and assessment of LNM for the present cohort study {#sec1}
--------------------------------------------------------------

A total of 880 patients with uterine corpus malignancy were treated at the National Hospital Organization, Hokkaido Cancer Center between January 2003 and December 2016. We excluded 85 who had carcinosarcoma/sarcoma, and 41 who did not undergo surgical treatment. A total of 754 patients with endometrial cancer thus underwent surgical treatment. Of these 754 patients, 199 (26.4%) did not undergo lymph node dissection, 175 (23.2%) underwent PLN dissection (PLND) alone, and 380 (50.4%) underwent both PLNDs and PAN dissections (PANDs). Information concerning age, body mass index (BMI), the International Federation of Gynecology and Obstetrics (FIGO) stage, extent of surgery, and final pathological reports was collected by review of the relevant medical records. Lymph node sites were classified into PLN and PAN. PAN was further classified into low PAN and high PAN, indicating the region between the bifurcation of the aorta and the inferior mesenteric artery, and the region between the inferior mesenteric artery and the renal vessels, respectively. The survival outcome measure was overall survival (OS), defined as the time from the starting date of initial treatment to death. Patients known to still be alive or lost to follow-up at the time of analysis were censored at their last follow-up. Survival rates were estimated by the Kaplan-Meier method. Unpaired numerical data were compared using Student\'s unpaired t-tests. Variables were compared between groups using Fisher\'s exact test, χ^2^ test, or Mann-Whitney U tests. The significance level was set at 0.05. Statistical analyses were performed using StatView J-5. 0 PPC (SAS Institute, Cary, NC, USA).

2. Study selection and data extraction for a pooled analysis {#sec2}
------------------------------------------------------------

Using the keywords "endometrial cancer," "uterine cancer," "para-aortic lymphadenectomy," and "para-aortic lymph node metastasis," a PubMed search for English language publications published from 1983 to 2016 was conducted. Research published only in abstract format was not included. Publications were selected for initial review if the study showed its proportion of PAN metastasis. If 2 or more reports overlapping study periods from the same institution were identified, only 1 was selected in the analysis to avoid duplication of cases. If the PAN metastasis rate was calculated based on background data with an unknown probability of patients with PAND in the study population, that study was excluded from the present analysis. In a nutshell, published studies with information on all the following were included in the analysis: 1) number of patients negative for PLN and PAN metastases (PLN−PAN−); 2) number of patients negative for PLN metastasis but positive for PAN metastasis (PLN−PAN+); 3) number of patients positive for PLN metastasis but negative for PAN metastasis (PLN+PAN−); and 4) number of patients positive for PLN and PAN metastases (PLN+PAN+). These 4 values must have been obtained based exclusively on data for patients who underwent both PLNDs and PANDs. Twenty-five eligible reports were finally identified from the pooled data \[[@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29][@B30]\].

RESULTS
=======

The clinical and pathological characteristics of the 754 patients treated by surgery are shown in [Table 1](#T1){ref-type="table"}. The median age was 59 years (range: 20--93 years). Grouping according to the extent of surgery showed that 32.7% of patients aged [\>]{.ul}70 years were in the no-lymphadenectomy group, 22.9% in the PLND group, and 6.6% in the PLND+PAND group (p\<0.001). The mean BMI of all patients was 24.7 kg/m^2^ (standard deviation: 5.65). The proportions of patients with a BMI [\>]{.ul}30 kg/m^2^ were 20.6% in the no-lymphadenectomy group, 17.1% in the PLND group, and 12.4% in the PLND+PAND group (p=0.029). In terms of histological variants, there were 413 (54.8%) grade 1 endometrioid adenocarcinomas (G1), 149 (19.8%) grade 2 endometrioid adenocarcinomas (G2), and 89 (11.8%) grade 3 endometrioid adenocarcinomas (G3), and 103 (13.6%) non-endometrioid carcinomas. The incidence rates of grade 3/non-endometrioid carcinomas were 21.1% in the no-lymphadenectomy group, 14.3% in the PLND group, and 32.9% in the PLND+PAND group (p\<0.001). The overall proportions of FIGO stage were 581 (77.0%) in stage I, 37 (4.9%) in stage II, 100 (13.3%) in stage III, and 36 (4.8%) in stage IV. The incidence rates of patients with stage IA disease were 66.3% in the no-lymphadenectomy group, 69.1% in the PLND group, and 49.5% in the PLND+PAND group, while the rates of stage III/IV disease were 12.0% in the no-lymphadenectomy group, 11.4% in the PLND group, and 24.2% in the PLND+PAND group (p\<0.001).

###### Characteristics of 754 patients with endometrial cancer who underwent surgical treatment

![](jgo-28-e59-i001)

  Characteristic        LND (−) (n=199)        PLND alone (n=175)   PLND+PAND (n=380)   p-value      
  --------------------- ---------------------- -------------------- ------------------- ------------ ---------
  Age (yr)              59.0 (20--93)          60.0 (33--83)        58.5 (28--76)                    
                        ≥70                    65 (32.7)            40 (22.9)           25 (6.6)     \<0.001
                        ≥75                    40 (20.1)            19 (10.9)           1 (0.3)      \<0.001
  BMI (kg/m^2^)         23.6 (15.5--51.8)      23.1 (15.5--46.6)    23.8 (13.4--44.9)                
                        \>30                   41 (20.6)            30 (17.1)           47 (12.4)    0.029
                        \>35                   17 (8.5)             9 (5.1)             14 (3.7)     0.046
  Final pathology                                                                       \<0.001      
                        Endometrioid grade 1   129 (64.8)           120 (68.6)          164 (43.2)   
                        Endometrioid grade 2   28 (14.1)            30 (17.1)           91 (23.9)    
                        Endometrioid grade 3   16 (8.0)             8 (4.6)             65 (17.1)    
                        Other                  26 (13.1)            17 (9.7)            60 (15.8)    
  Postoperative stage                                                                   \<0.001      
                        IA                     132 (66.3)           121 (69.1)          188 (49.5)   
                        IB                     34 (17.1)            27 (15.4)           79 (20.8)    
                        II                     9 (4.5)              7 (4.0)             21 (5.5)     
                        III                    7 (3.5)              11 (6.3)            82 (21.6)    
                        IV                     17 (8.5)             9 (5.1)             10 (2.6)     

Values are presented as median (range) or number (%).

BMI, body mass index; LND, lymph node dissection; PAND, para-aortic lymph node dissection; PLND, pelvic lymph node dissection.

The surgical results for the 380 patients who underwent both PLNDs and PANDs are shown in [Table 2](#T2){ref-type="table"}. Removal of PAN up to the renal vein was performed in 375 (98.7%) patients, while the remaining 5 (1.3%) patients (1 PLN−PAN−, 1 PLN−PAN+, 3 PLN+PAN+) did not undergo removal of PAN above the inferior mesenteric artery. The median numbers of PLN and PAN removed were 41 (range: 11--107) and 16 (range: 1--65), respectively. The overall LNM rate was 16.9% (64/380) and the PAN metastasis rate was 10.3% (39/380). The most frequent lymphatic spread pattern was PLN+PAN+ (7.9%), followed by PLN+PAN− (6.6%), and PLN−PAN+ (2.4%). The proportion of PAN metastasis in patients without PLN metastasis were 2.8% (9/325). Of the 9 patients with PLN−PAN+, 3 (33.3%) had peritoneal disease. Complete surgery, including removal of peritoneal disease, was performed in all 3 cases, and one patient achieved long-term disease-free survival ([Table 3](#T3){ref-type="table"}).

###### Surgical results of 380 patients who underwent PLND and PAND

![](jgo-28-e59-i002)

  Characteristic               Value (n=380)                   
  ---------------------------- ------------------------------- ----------------
  Type of PAND                                                 
                               Low PAN alone (below the IMA)   5
                               Low PAN and high PAN            375
  No. of lymph nodes removed                                   
                               PLN                             41 (11--107)
                               PAN                             16 (1--65)
                               Total                           56.5 (18--131)
  Lymphatic spread pattern                                     
                               PLN−PAN−                        316 (83.1)
                               PLN−PAN+                        9 (2.4)
                               PLN+PAN−                        25 (6.6)
                               PLN+PAN+                        30 (7.9)

Values are presented as median (range) or number (%).

IMA, inferior mesenteric artery; PAN, para-aortic lymph node; PAND, para-aortic lymph node dissection; PLN, pelvic lymph node; PLND, pelvic lymph node dissection.

###### Profile of the 9 patients with PLN−PAN+

![](jgo-28-e59-i003)

  Age (yr)   Peritoneal disease   Final histological type   Myometrial invasion   Cervical involvement   LVSI   Adnexal metastasis   Peritoneal washing   Preoperative histological type   Myometrial invasion (MRI)   Radiological signs of extrauterine disease   Outcome   OS (M)
  ---------- -------------------- ------------------------- --------------------- ---------------------- ------ -------------------- -------------------- -------------------------------- --------------------------- -------------------------------------------- --------- --------
  46         \+                   G2                        \<1/2                 \+                     \+     \+                   \+                   G2                               \>1/2                       −                                            NED       75
  70         \+                   S                         \>1/2                 \+                     \+     −                    \+                   S                                \>1/2                       \+                                           DOD       8
  63         \+                   G2                        \>1/2                 −                      \+     \+                   \+                   G1                               \>1/2                       \+                                           NED       7
  67         −                    G2                        \>1/2                 \+                     \+     \+                   \+                   G1                               \>1/2                       \+                                           DOD       15
  70         −                    Mixed                     \<1/2                 −                      \+     \+                   \+                   S                                \>1/2                       −                                            NED       9
  40         −                    G2                        \>1/2                 −                      \+     −                    \+                   G1                               \>1/2                       −                                            DOD       43
  55         −                    G1                        \>1/2                 −                      \+     −                    −                    G1                               \>1/2                       −                                            NED       63
  63         −                    G1                        \>1/2                 \+                     \+     −                    −                    G1                               \>1/2                       −                                            NED       61
  61         −                    G1                        \>1/2                 −                      \+     −                    −                    G2                               \>1/2                       −                                            NED       22

DOD, died of disease; G1, grade 1 endometrioid adenocarcinoma; G2, grade 2 endometrioid adenocarcinoma; LVSI, lympho-vascular space invasion; M, month; Mixed, mixed epithelial carcinoma; MRI, magnetic resonance imaging; NED, no evidence of disease; OS, overall survival; PAN, para-aortic lymph node; PLN, pelvic lymph node; S, serous adenocarcinoma.

The lymphatic spread patterns in the 60 patients who underwent PAND up to the renal vein and were diagnosed with LNM are shown in [Fig. 1](#F1){ref-type="fig"}. Thirty-five (58.3%) had PAN metastasis. Of these 35 patients, 28 (80.0%) had high PAN metastasis.

![Lymphatic spread pattern in 60 patients who underwent PAND up to the renal vein and were diagnosed with LNM.\
LNM, lymph node metastasis; PAN, para-aortic lymph node; PAND, para-aortic lymph node dissection; PLN, pelvic lymph node.](jgo-28-e59-g001){#F1}

Kaplan-Meier OS curves by lymphatic spread pattern are shown in [Fig. 2](#F2){ref-type="fig"}. The overall median follow-up period was 58 months. The 5-year OS rates were 96.5% in PLN−PAN− patients, 77.6% in PLN+PAN−, 63.4% in PLN+PAN+, and 53.6% in PLN−PAN+ patients. There was no significant difference in survival between the PLN−PAN+ and the PLN+PAN+ groups (log-rank test, p=0.410), and no significant difference in survival between the PLN−PAN+ and PLN+PAN− groups (log-rank test, p=0.400).

![Kaplan-Meier OS curves according to lymphatic spread pattern.\
OS, overall survival; PAN, para-aortic lymph node; PLN, pelvic lymph node.](jgo-28-e59-g002){#F2}

The results of the pooled analysis are shown in [Table 4](#T4){ref-type="table"}. A total of 6,532 patients with endometrial cancer who underwent both PLNDs and PANDs were identified from the pooled data \[[@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29][@B30]\]. The overall LNM rate was 16.7% (1,092/6,532) and the PAN metastasis rate was 9.7% (634/6,532). The PAN metastasis rates were 8.5% (174/2,056) among studies with the number of PAN removed \<10 and 12.7% (280/2,197) among studies with the number of PAN removed [\>]{.ul}10. The proportion of PAN metastasis in patients without PLN metastasis was 2.7% (149/5,599). The PAN metastasis rates in patients without PLN metastasis were 1.6% (29/1,781) among studies with the number of PAN removed \<10 and 3.5% (64/1,819) among studies with the number of PAN removed [\>]{.ul}10.

###### Results of pooled analysis: lymphatic spread pattern in endometrial cancer according to number of PANs removed

![](jgo-28-e59-i004)

  Author                              Year                           No.     FIGO stage III/IV (%)   NE histology (%)   No. of PLNs removed^\*^   No. of PANs removed^\*^   A        B       C     D     B/A+B (%)   
  ----------------------------------- ------------------------------ ------- ----------------------- ------------------ ------------------------- ------------------------- -------- ------- ----- ----- ----------- -----
  No. of PAN removed: \<10                                                                                                                                                                                           
                                      Larson et al. \[[@B6]\]        1993    50                      28                 0                         13                        5        50      0     2     8           0.0
                                      Fanning et al. \[[@B7]\]       1996    60                      8                  0                         21                        7        55      0     5     0           0.0
                                      Yokoyama et al. \[[@B8]\]      1997    63                      13                 3                         14                        6        45      4     6     8           8.2
                                      Lee et al. \[[@B9]\]           2009    349                     NA                 0                         (22.8)                    (9.5)    277     7     26    39          2.5
                                      Abu-Rustum et al. \[[@B10]\]   2009    847                     NA                 NA                        16                        5        722     12    52    61          1.6
                                      Chiang et al. \[[@B11]\]       2011    171                     22                 6                         17                        5        154     2     12    3           1.3
                                      Solmaz et al. \[[@B12]\]       2015    516                     NA                 0                         22                        8.5      449     4     37    26          0.9
                                      Subtotal                               2,056                                                                                                   1,752   29    140   145         1.6
  No. of PAN removed: not available                                                                                                                                                                                  
                                      Chen and Lee \[[@B13]\]        1983    74                      NA                 11                        NA                        NA       63      3     3     5           4.5
                                      Creasman et al. \[[@B14]\]     1987    621                     22                 4                         NA                        NA       551     12    36    22          3.9
                                      Ayhan et al. \[[@B15]\]        1995    209                     NA                 NA                        NA                        NA       173     6     17    13          3.4
                                      Hirahatake et al. \[[@B16]\]   1997    200                     42                 4                         NA                        NA       158     2     24    16          1.3
                                      Milam et al. \[[@B17]\]        2012    582                     11                 0                         NA                        NA       520     12    31    19          2.3
                                      Sueoka et al. \[[@B18]\]       2015    502                     17                 18                        NA                        NA       422     15    27    38          3.4
                                      Mahdi et al. \[[@B19]\]        2015    91                      NA                 NA                        NA                        NA       56      6     18    11          9.7
                                      Subtotal                               2,279                                                                                                   1,943   56    156   124         2.8
  No. of PAN removed: \>10                                                                                                                                                                                           
                                      Onda et al. \[[@B20]\]         1997    173                     24%                1                         (37.9)                    (28.7)   143     2     10    18          1.4
                                      Matsumoto et al. \[[@B21]\]    2002    106                     NA                 5                         (36.8)                    (30.5)   79      2     7     18          2.5
                                      Mariani et al. \[[@B22]\]      2008    281                     NA                 NA                        35                        17       218     10    24    29          4.4
                                      Fujimoto et al. \[[@B23]\]     2009    355                     25                 0                         42                        19       306     7     20    22          2.2
                                      Dogan et al. \[[@B24]\]        2012    161                     21                 21                        (49.5)                    (19.0)   143     2     11    5           1.4
                                      Odagiri et al. \[[@B25]\]      2014    266                     NA                 17                        62.5                      20       224     7     16    19          3.0
                                      Altay et al. \[[@B26]\]        2015    173                     NA                 27                        26                        12       135     7     12    19          4.9
                                      Tomisato et al. \[[@B27]\]     2014    260                     46                 17                        50                        22       169     9     34    48          5.1
                                      Fotopoulou et al. \[[@B28]\]   2015    128                     15                 24                        29                        21.5     101     4     8     15          3.9
                                      Sautua et al. \[[@B29]\]       2015    90                      NA                 NA                        (11.9)                    (10.7)   77      6     3     4           7.2
                                      Alay et al. \[[@B30]\]         2015    204                     26                 23                        (44.1)                    (24.9)   160     8     17    19          4.8
                                      Subtotal                               2,197                                                                                          1,755    64      162   216   3.5         
  Total                                                              6,532                                                                        5,450                     149      458     485   2.7               

FIGO, International Federation of Gynecology and Obstetrics; NA, not available; NE, non-endometrioid; PAN, para-aortic lymph node; PLN, pelvic lymph node.

^\*^Values are presented as median (mean).

DISCUSSION
==========

In this study, we focused on the probability of PAN metastasis in endometrial cancer patients without PLN metastasis, in light of the increasing use of SLN mapping by cervical tracer injection in Western countries. As noted above, the ability of cervical injection to assess PAN status is poor. Before discussing a significance of the probability, we considered our results in light of previous studies in patients at risk of LNM. In our study, PAND was implemented at the discretion of the attending surgeons and was performed in 50.4% of patients who underwent surgical treatment. The overall LNM rate was 16.9% among patients who underwent both PLNDs and PANDs, which was in close agreement with the rate of 16.7% derived from the pooled analysis. During the last decade, the Mayo criteria have been recognized as the standard decision-making model for implementing lymphadenectomy in patients with endometrial cancer. These criteria divide patients into "not at-risk for lymph node metastasis" and "at-risk for lymph node metastasis" groups. The former includes cases of G1/G2, \<50% myoinvasion, and tumor diameter \<2 cm, while the latter includes all other cases \[[@B22][@B31]\]. According to their protocol, lymphadenectomy is not recommended for the "not at-risk" group, but both pelvic and para-aortic lymphadenectomies are recommended for the "at-risk" group. Kumar et al. \[[@B31]\] found prevalence of PLN and PAN metastases of 17% and 12%, respectively, among patients at risk of LNM determined by the Mayo criteria, compared with 14.5% and 10.3%, respectively, in our cohort, suggesting that our results do not overestimate the true probability of PAN metastasis in patients without PLN metastasis.

The incidence of PAN metastasis in patients without PLN metastasis was 2.8% in our cohort, which was in close agreement with 2.7% in the pooled analysis. Previous studies \[[@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29][@B30]\] with sufficient numbers of PAN removed (\>10) found incidences up to 3.5%. Overall, these results suggest that the probability of PAN metastasis in the absence of PLN metastasis is remote, but not improbable, in patients at risk of LNM. SLN mapping by cervical tracer injection should thus be performed cautiously in such a population. Our results also demonstrated the significance of the upper para-aortic region. To the best of our knowledge, SLNs in the upper para-aortic region have not been detected by cervical injection, and cervical injection lacks the ability to detect para-aortic SLNs above the inferior mesenteric artery, which represents a major disadvantage of this procedure.

SLN mapping by cervical injection could be considered safe if the implications of PLN−PAN+ were negligible, and the relevance of PLN−PAN+ should thus be assessed in light of not only its probability, but also its prognostic risk. There was no difference in survival between the PLN−PAN+ and PLN+PAN+ groups in the present study. Tomisato et al. \[[@B27]\] also showed a 5-year progression-free survival rate of 44.4% for PLN−PAN+ (compared with 87.1% for PLN−PAN−, 67.5% for PLN+PAN−, and 33.2% for PAN+PAN+), with no significant difference in survival between the PLN−PAN+ and PLN+PAN+ groups, despite there being few PLN−PAN+ cases. These results were consistent with ours, and suggest that the prognosis of patients with PLN−PAN+ status is poor. A group of patients with endometrial cancer at risk of LNM thus consists of a minority (around 3%) of PLN−PAN+ cases at risk of a poor prognosis.

In light of the increasing attention given to SLN mapping using cervical tracer injection, it may be necessary to create a novel patient category, i.e., "at-risk but not at-risk for PAN metastasis." We suggest that this type of SLN mapping should only be applied in patients at negligible risk of PAN metastasis \[[@B32]\]. The probability of isolated PAN metastasis may be deemed low enough to forego the need to determine PAN status. However, this could be considered to be a utilitarian approach with an emphasis on economic efficiency, at the potential expense of a minority of patients with a poor prognosis, in case of PLN−PAN+. The utilitarian concept threatens medical evolution by reducing treatment for patients at risk of a poor prognosis. Regarding the treatment strategy for PLN−PAN+ patients, we wish to question the emphasis placed on the low prevalence of PLN−PAN+ and ask if its prognostic risk has been fairly assessed. We suggest that gynecologic oncologists should consider establishing treatment strategies aimed at the specific care of minorities, such as patients with PLN−PAN+ status.

The current study had some limitations. The number of patients was too small to produce conclusive results. Furthermore, the study was inevitably subject to selection bias because of its retrospective, single-institution nature. It should be noted that the proportion of PLN−PAN+ in this study does not represent the corresponding one in the general population which include both "not at-risk" and "at-risk" groups. However, the issue of PAN metastasis might not be studied in a general population that includes "not at-risk" patients because the probability of PAN metastasis is greatly reduced in this population, and the implication of PLN−PAN+ is subsequently undervalued. In addition, there were no strict rules for applying PLNDs and PANDs in our patients. However, we performed a systematic review to overcome this weakness. Our patient group with PLND and PAND is likely to resemble the "at-risk" groups identified in other studies. In conclusion, PAN metastasis may occur in patients without PLN metastasis, with a non-negligible effect on survival.
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